CONTINUOUS ADMINISTRATION OF ENDOSTAR PLUS GP CHEMOTHERAPY IN LOCAL ADVANCED OR METASTATIC LUNG SQUAMOUS CELL CARCINOMA

Hong Shen,Jing Zhao,Shan-Shan Weng,Xue-Feng Fang,Yi-Yang Zhang,Jian-Jin Huang

2016-01-01

Acta medica mediterranea

Abstract:Introduction: In squamous cell lung cancer (SQCLC), the current first-line therapy is considered platinum-based doublet chemotherapy and the benefit is limited. Aim of our study is to compare the effect of patients with local advanced or metastatic SQCLC, in comparable groups of patients treated with systemic chemotherapy containing gemcitabine/cisplatin (GP) or GP+ Endostar. Materials and methods: All patients with local advanced or metastatic SQCLC who had undergone GP+ continuous administration of Endostar from September 2009 to January 2014 were evaluated. The GP group was constituted by selecting patients with local advanced or metastatic SQCLC treated with GP chemotherapy during the same period. Results: Fifty-two patients were retrospectively included in the GP group and were compared with 98 patients who had undergone continuous administration of Endostar +GP and were evaluated prospectively. All characteristics were comparable. Median follow-up was 60 months in the GP group versus 58 months in the Endostar +GP group. The response rate (RR) was 34.7% in Endostar +GP group and 34.6% in the GP group. The disease control rate (DCR) was 89.7% in Endostar +GP group and 80.8% in the GP group. Both the RR and DCR were not found to be significantly different with each other. Median progression free survival (PFS) was 5.56 months in the GP group versus 7.23 months in the Endostar +GP group. Discussion: The combination of continuous infusion of Endostar with chemotherapy can improve the PFS in local advanced or metastatic SQCLC patients without increasing adverse events.